0625/26SCR019-18/R12RGB
Media Highlights
From the 2026 ASCO® Annual Meeting
7
Meredith Pelster, MD, MSCI
SCRI
Media Outlet Date Article / Coverage
BioSpace 5/26/26 All Eyes on Revolution, Bispecific Antibodies and
More at ASCO26
BioSpace 6/1/26 ASCO: Biopharma Has Pancreatic Cancer 'Surrounded' As
Immuneering's Drug Adds 9 Quality Months
BioSpace 6/1/26 ASCO: Revolution Poised to Capture Ras Space As
Pancreatic Cancer Dataset 'Derisks' Approval
Patient Daily 6/2/26 Immuneering's Pancreatic Cancer Drug Shows Extended
Survival in Phase 2a Trial
Patient Daily 5/26/26 ASCO 2026 to Spotlight Revolution Medicines and
Bispecific Antibody Advances
Sarah Premji, MD
SCRI
Media Outlet Date Article / Coverage
Breast Cancers
Today
6/22/26 ASCO 2026 Brings Wins in Personalized Medicine for Breast
Cancer, Tailoring Treatment to the Individual Patient, and In
Supportive Care
Authored by Sarah Premji, MD, Mythili Shastry, PhD, Chelsea
Goodenough, PhD, Erika Hamilton, MD
Cancer Nursing
Today
6/22/26 Targeting CDH6: A New ADC Approach in Gynecologic
Cancer
DocWire News 5/20/26 HR+ Breast Cancer at ASCO 2026: Emerging Data to Watch
DocWire News 5/26/26 ASCO 2026 Preview: Breakthroughs in TNBC and HER2+
Breast Cancer
DocWire News 6/10/26 Biparatopic HER2 Targeting in Action: Anbenitamab's
Phase 3 Breakthrough
Continued ➔
